A Phase 1, Open Label First in Human Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK 1 Inhibitor GRC 54276 Alone and in Combination with Anti-Pd-1 Monoclonal Antibody Pembrolizumab or Anti-Pd-L1 Atezolizumab in Subjects with Advanced Solid Tumors and Lymphomas

Protocol No
GLENMARK-GRC-54276-101
Phase
I
Summary

This project is being done to determine the dose of study drug that provides the most
benefit with the least amount of side effects, which will then be given during Part 2 of the study.

Description
A Phase 1 Study of Hpk1 GRC54276 in Combination with Anti-Pd-1 in Patients with Advanced Solid Tumors
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL